Compare TG Therapeutics Inc (TGTX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Williams Companies Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Williams Companies Inc trades at $75.31 (market cap $91.92B). The key difference: Williams Companies Inc is far larger — about 11× TG Therapeutics Inc's market cap, and Williams Companies Inc pays a 2.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WMB | |
|---|---|---|
Market Cap | $8.36B | $91.92B |
Sector | Health | Energy |
52-Week High | $59.06 | $79.40 |
52-Week Low | $26.94 | $56.51 |
Enterprise Value | $8.57B | $122.55B |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
WMB trades at $75.83, up 2.27% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings but maintains robust profitability with a 25.18% net income margin. Recent developments include the $5.5 billion acquisition of Momentum Midstream, enhancing its natural gas infrastructure, while a court ruling vacated a key permit for the NESE pipeline project.
The stock offers growth exposure to natural gas demand driven by LNG exports and AI infrastructure, with a consensus price target of $88.14 implying 16% upside. Risks include regulatory hurdles for pipeline projects and high debt levels, but strong cash flow supports dividends and expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
